US20130152309A1 - Antibacterial wound dressing - Google Patents
Antibacterial wound dressing Download PDFInfo
- Publication number
- US20130152309A1 US20130152309A1 US13/767,713 US201313767713A US2013152309A1 US 20130152309 A1 US20130152309 A1 US 20130152309A1 US 201313767713 A US201313767713 A US 201313767713A US 2013152309 A1 US2013152309 A1 US 2013152309A1
- Authority
- US
- United States
- Prior art keywords
- fibres
- process according
- gel
- wound dressing
- forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- One aspect is the actual colour of the product, namely the need to have a product having a colour acceptable to the consumer.
- the second aspect is the need to produce a product having a uniform appearance.
- the third aspect is the stability (shelf-life) of the colour of the dressing within whatever packaging is used to package the dressing. If fibres are blended, and both fibres are white, any imperfection in the blending is not noticed by the consumer.
- the time interval between the beginning of the dipping of the gel-forming fibre into the silver-containing solution and the moment at which sufficient gel-forming fibre to form the wound dressing is entirely immersed is desirably not more than about 10 seconds, preferably 5 seconds or less. For practical purposes the time interval is usually about 2 to 3 seconds.
- the silver content of the bath may be of the order of 0.1 to 1% w/v, preferably 0.25 to 0.5% w/v.
- a typical solution may for example comprise 2.71 IMS (industrial methylated spirit), 1.81 water and 25 g AgNO 3 to give a concentration of 0.35% w/v silver.
Abstract
An antibacterial wound dressing is based on or derived from gel-forming fibres such as carboxymethyl cellulose or alginate fibres having silver ions linked thereto at some but not all of the exchangeable sites such that the distribution of silver ions over the exchangeable sites is substantially uniform. The silvered fibres for the wound dressing can be prepared by contacting an assembly of precursor gel-forming fibres having exchangeable sites under conditions which do not cause irreversible gelling of the fibres with an amount of a solution containing silver ions so as to link silver ions at some but not all of the exchangeable sites, the whole of the assembly of precursor gel-forming fibres being contacted essentially simultaneously with the entire solution containing silver ions.
Description
- The present invention relates to wound dressings, in particular to an antibacterial wound dressing based on silvered gel-forming fibres, and to an improved process for the manufacture of such a wound dressing.
- It has been known for many years that silver is a useful antibacterial agent with broad-spectrum activity together with compatibility with mammalian tissue, and there have been many proposals to incorporate silver into wound dressings to obtain the to advantage of the bactericidal properties of silver in a wound dressing. In addition, silver has been applied to fibrous material previously for non-wound dressing purposes, usually for the purpose of enhancing electrical conductivity, see for example UK-A-927,115, WO-A-92/16589, DE-C-2,639,287, U.S. Pat. No. 5,302,415, U.S. Pat. No. 5,186,984, U.S. Pat. No. 4,752,536, U.S. Pat. No. 4,643,918, JP-010207473A, and JP-020153076. Silver has been applied to such fibres, which are generally not gel-forming, in a variety of ways in those references, some of which involve immersing the fibres into a silver solution, but detail of the procedures used is often lacking.
- Carboxymethyl cellulose, in particular carboxymethylated lyocell, has the ability to absorb a great deal of water and to form a gel on its surface. This property of the material has been found to be particularly advantageous in the formation of wound dressings that are both absorbent and gel-forming. The carboxymethylation of cellulose is described in WO-A-93/12275, and the use of carboxymethyl cellulose for wound dressings is described in WO-A-94/16746. Calcium (or sodium/calcium) alginate is another material useful in the formation of wound dressings, because of its absorbency and gelling capability. Gel-forming fibres for use in wound dressings are water-absorbent fibres which become moist and slippery or gelatinous upon the uptake of wound exudate and thus reduce the tendency for the surrounding fibres to adhere to the wound. The gel-forming fibres may also swell. Gel-forming fibres can be of the type which retain their structural integrity on absorption of exudate or can be of the type which lose their fibrous form and become a structureless gel or solution on absorption of exudate. GB-A-1,328,088, WO-A-91/11206, WO-A-92/22285, JP-A-4146218 and WO-A-02/36866 disclose the incorporation of silver into calcium sodium alginate, WO-A-01/24839 discloses carboxymethyl cellulose fibres containing silver chloride and WO-A-02/43743 discloses incorporating silver into a polymer which can be carboxymethyl cellulose or an alginate, the contents of these documents being incorporated by reference herein.
- There have, however, been particular problems associated with the use of silver in wound dressings because of the fact that silver compounds are light-sensitive and darken on exposure to light. This can result in the production of products which have an unattractive visual aspect, even if they are technically suitable for use as wound dressings.
- There are three particular aspects of the darkening of the silver compound in light which need to be addressed when seeking to produce a commercially acceptable silvered wound dressing. One aspect is the actual colour of the product, namely the need to have a product having a colour acceptable to the consumer. The second aspect is the need to produce a product having a uniform appearance. The third aspect is the stability (shelf-life) of the colour of the dressing within whatever packaging is used to package the dressing. If fibres are blended, and both fibres are white, any imperfection in the blending is not noticed by the consumer. Whilst this is primarily a visual issue, extremes of streakiness or discoloration within a wound dressing could be an indicator of incomplete or inadequate silver additions to the wound dressing or parts of it, or even the presence of excessive amounts of silver in some areas, which could indicate potential problems in use. Silver as an antibacterial material should be used in measured dosages, and this would not be the case if the silver level varied from dressing to dressing.
- Kiers are well known for use in fibre treatment processes; for example, it is well known that cellulosic fibre can be dyed by being placed into a kier and the dye liquor pumped through the kier to give a product having a uniformly dyed appearance. A kier is a sealed container having inlets and outlets; it is capable of being pressurised and heated if required and is incorporated into a circuit such that liquor can be pumped through the kier. Located within the kier is a porous basket in the faun of a stainless steel mesh and the product to be treated is packed consistently in the mesh to ensure uniform and even flow of liquor through the mesh during the pumping process.
- Attempts were made, therefore, by the applicant to apply the silver to carboxymethyl cellulose fibre in a kier just as though the carboxymethyl cellulose was being dyed with a dye, using a solution of a silver-containing compound (industrial methylated spirit (IMS), H2O+AgNO3) in the kier. The silver-containing liquor was pumped from the centre towards the periphery. In that procedure a basket containing 1.25 kg of the carboxymethyl cellulose fibre was placed within the kier prior to charging the kier with liquor. Then 10.4 litres of a solution of (IMS, H2O+AgNO3) made up of 6.41 IMS, 4.01 water, 25 g AgNO3 at a silver concentration of 0.240 w/v and a temperature of 30° C. were pumped through the kier, which had a capacity of about 12 litres. After the liquor had been pumped around the circuit for 30 minutes, the liquor was drained out of the fibre and the product was moved immediately to subsequent stages, including the application of a textile finish and drying. After all of the subsequent treatments had taken place the fibre was removed and exposed to light. It was found that the fibre was not uniform in its silver take-up. The product produced by this process was found to be very streaky.
- Attempts were therefore made to alter the kier process by using an upward-flow basket which fed the liquor from below rather than from the centre. Such a procedure was found to improve the product in the sense that it was less streaky but there was a distinct gradation of silver take-up from the bottom to the top of the basket.
- It is an object of the present invention to provide an anti-bacterial wound dressing based on or derived from silvered gel-forming fibres in which the above disadvantages are reduced or substantially obviated. It is a further object of the present invention to s provide silvered fibres for an antibacterial wound dressing based on silvered gel-forming fibres in which the above disadvantages are reduced or substantially obviated.
- We have found that superior wound dressings can be obtained from silvered gel-forming fibres having more sites capable of taking up silver ions than there are silver ions available in the solution used for silvering, so that not all the sites take up silver ions in the silvering operation, by having the silver ions that are taken up distributed substantially uniformly over the sites capable of taking them up.
- Antibacterial wound dressings according to the invention are thus derived from gel-forming fibres having silver ions linked thereto at some but not all exchangeable sites and are characterized in that the distribution of silver ions over the exchangeable sites is substantially uniform.
- Usually, only a minority of the sites on the gel-forming fibres capable of ionic exchange with silver ions are actually silvered in making the wound dressings of the invention, and frequently not more than 20%, often not more than 10%, of such sites are silvered.
- We have also found that superior silvered fibres for wound dressings can be obtained if the contacting of the gel-forming fibres having exchangeable sites capable of exchange with silver ions to silver the fibres with the solution for silvering is carried out in such a way that the entire solution for silvering is contacted essentially simultaneously with the entire amount of gel-forming fibres to form the wound dressing, rather than being contacted gradually or partially.
- According to the invention, therefore, a process for producing silvered fibres for antibacterial, wound dressings based on silvered gel-forming fibres includes the steps of:
-
- (i) forming an assembly of precursor gel-forming fibres having thereon exchangeable sites capable of exchange with silver ions to link silver ions to the fibres, and
- (ii) contacting the assembly of precursor gel-forming fibres with a solution containing silver ions, under conditions which do not cause irreversible gelling of the fibres, thereby to link silver ions to the fibres at exchangeable sites,
and it is characterised in that the whole of the assembly of precursor gel-forming fibres to form the wound dressing is contacted essentially simultaneously with the entire solution containing silver ions, the solution containing silver ions being used in an amount such that only enough silver ions are present to link with some but not all of the exchangeable sites on the precursor gel-forming fibres. The essentially simultaneous contacting may be achieved as a batch process by rapidly dipping and immersing in the silver-containing solution the gel-forming fibres to form the wound dressing.
- Thus, in one embodiment, the present invention provides a process for the production of an antibacterial wound dressing based on silvered gel-forming fibres, which process includes the following steps in sequence:
-
- (i) forming precursor fibres having thereon sites capable of ionic exchange with silver ions to form a silvered tow, and
- (ii) silvering the fibres using a silver-containing solution which does not cause irreversible gelling of the fibres,
characterised in that, in order to give a uniform take-up of silver, the fibres are dunked into the silver solution, by lowering the fibres directly into the solution and pushing the fibres immediately below the surface of the solution. The resulting silvered fibres may then be processed, for example in conventional steps, to form the wound dressing.
- Gel-forming fibres suitable for use in wound dressings tend to be extremely reactive towards silver ions, that is to say the silver ions bind very quickly and very firmly to the ion-exchange sites on the fibres. We have found that, in contrast to dye molecules applied in a kier, there is essentially no redistribution of silver ions after initial attachment. This means that, if such fibres are brought slowly or gradually into contact with a solution containing a limited amount of silver ions, the portions of the fibres first in contact with silver-containing solution will take up relatively large quantities of silver ions so that those portions of the fibres coming into contact with the silver-containing solution last may have hardly any take-up of silver at all. The resulting fibres will not have a uniform coloration initially and will darken to different degrees. It would not be possible to overcome this drawback by using a larger quantity of silver, because that could lead to over-silvering of the parts of the fibres first in contact with the solution, with consequent lack of uniformity of silver distribution in the product, or to the failure to exhaust the silver content of the solution, with consequent problems over disposal of effluent as well as waste of valuable silver.
- It is also important that the volume of the solution is adjusted so that essentially all parts of it contact gel-forming fibres essentially simultaneously. If the volume of the solution is large compared to the volume that is taken up by the gel-forming fibres, so that some parts of the solution are relatively remote from any fibres, silver ions in that part will tend to diffuse towards and interact with the fibres first encountered and give heavier deposition on those fibres, spoiling the unitarim distribution desired.
- It is particularly preferred for the volume of the solution with which the precursor gel-forming fibres are contacted to be adjusted such that essentially all the liquid of the solution is taken up by the water-absorbent gel-forming fibre, leaving essentially no free liquid. In such a situation there is essentially no waste solution to be disposed of at this stage.
- The time interval between the beginning of the dipping of the gel-forming fibre into the silver-containing solution and the moment at which sufficient gel-forming fibre to form the wound dressing is entirely immersed is desirably not more than about 10 seconds, preferably 5 seconds or less. For practical purposes the time interval is usually about 2 to 3 seconds.
- It has surprisingly been found that by dunking the fibre in an unconstrained manner into the solution, a very uniform silver take-up occurs. Furthermore, it has been found that it is desirable to minimise the amount of silver-containing solution to produce a silvered gel-forming fibre. The minimum volume of liquid required completely to cover any given amount of gel-forming fibre when the fibre is dunked into the solution can readily be determined by experiment. Once the minimum volume of liquid has been determined then that amount of silver-containing solution is made up and the fibre is simply dunked into the solution so that the fibre takes up the solution, that is to say it fills the solution within the container in which it is held. This means that there is minimal wasted solution and the amount of silver-containing solution which has to be handled is also minimised.
- The silver-containing solution is preferably held in a container, which may be a closed container or an open container. The size of the container, and hence the volume of solution it contains, and the amount of gel-forming fibre axe correlated so that the entire volume of solution contacts fibres essentially simultaneously.
- The gel-forming fibre is preferably a carboxymethylated cellulose (CMC) fibre. The CMC derived from lyocell generally has a degree of substitution of from 0.1 to 0.5, preferably 0.2 to 0.4. This gives a sufficient number of carboxylate groups that the gelling and absorbency properties are adequate for use as a wound dressing but without being so high that a substantial amount of the fibre becomes soluble. The CMC may be derived from cellulose, preferably from lyocell, by carboxyrnethylation. An alternative fibre is calcium or sodium/calcium alginate. The fibre which is contacted with the silver-forming solution is preferably dry, although it may be pre-wetted with a liquid which does not cause irreversible gelling. It is preferably in the form of a hank or tow but can alternatively be in staple (cut) fibre form, eg in standard, conventional lengths. To facilitate rapid fibre/solution contact the fibre is preferably used in relatively open, unconstrained form as opposed to tightly packed, constrained form. A hank of fibre, essentially a fairly loose bundle of continuous tow, or cut fibres achieves this. It is preferred in commercial operation to contact the solution, essentially simultaneously with enough fibre to form more than one wound dressing, for example to from 1,000 to 10,000 dressings. Thus, hanks up to many metres, for example 20 to 200 metres or more, long may be used. The fibre may have a soft finish thereon.
- The silver content of the silvered fibres is generally of the order of 0.01 to 10%, more narrowly 0.1 to 5%, preferably 0.5 to 2%, more preferably 0.9 to 1.5%, by weight. This enables good antibacterial activity to be achieved, without toxicity problems arising. This compares with a theoretical maximum of the order of 16% if all exchangeable sites on CMC lyocell with a degree of substitution of 0.3 are exchanged and about 38% if all exchangeable sites on conventional alginate fibre are exchanged.
- The contacting is carried out such that irreversible gelling of the fibres is avoided. It is preferred to use an aqueous organic solution for the silver ions, especially an aqueous alcoholic solution such as a mixture of ethyl alcohol and water. The water content of such a solution will generally not exceed about 50% by volume and is preferably 25 to 50% by volume, The silver is provided in the form of a source of soluble silver ions, for example a soluble silver salt of an acid, such as silver nitrate. Solubility at the required concentration in the solution to be used is essential, so that substances such as ceramic, ion-exchange resins containing silver or other insoluble silver sources should not be used. Broadly speaking, the silver content of the bath may be of the order of 0.1 to 1% w/v, preferably 0.25 to 0.5% w/v. A typical solution may for example comprise 2.71 IMS (industrial methylated spirit), 1.81 water and 25 g AgNO3 to give a concentration of 0.35% w/v silver.
- It may be desirable to stir or agitate the fibre or container during and/or immediately after addition so as to facilitate contact of all the fibre with all the solution.
- If a continuous process, rather than a batch process, is required, the fibre could be fed down a pipe or tube in co-current with the desired rate of feed of silver solution so as to give the desired amount of silver content on the gel-forming fibre.
- If no further wet processing steps are required prior to drying, the silvered fibres, suitably in the form of a tow, can then be squeezed out, preferably to approximately 1.5-21 remaining liquor per kg tow. This squeezing can be carried out manually or can be mechanised, for example by the application of vacuum pressure or via a press. Alternatively, the tow can be drained down and centrifuged. As the attachment of silver ions occurs very rapidly it is not necessary to remove the liquor from contact with the silvered fibres rapidly or essentially simultaneously in order to achieve a uniform silver deposition but in practice this may be preferred in case other unwanted effects occur.
- Little silver normally remains in the squeezed-out liquor, since virtually all has reacted with the gel-forming fibre. This can be shown by testing the liquor with NaCl solution, whereupon hardly any precipitation is observed.
- The resulting silvered tow of gel-forming fibre can then be processed into a wound dressing in known manner, for example as disclosed in WO-A-94/16746, the contents of which are incorporated herein by reference.
- Additional wet processing steps can be carried out on the silvered fibre prior to drying. For example, a conventional textile finish may preferably be applied in conventional amount (e.g. about 0.5% w/v) from an aqueous organic liquor (e.g. IMS/water) which does not cause irreversible gelling of the fibre. This may be preceded by a treatment conferring photostability, for example a treatment such as disclosed in WO 02/43743 (incorporated herein by reference) involving a metal halide such as sodium chloride.
- The dried silvered fibre, after cutting if necessary, typically into 50 mm staple lengths, may then be processed to form a nonwoven web, for example using a textile card and cross-folder. The web may then be treated to improve its strength, for example by needle bonding, before being cut into the dressing sizes required, for example squares typically of 10 cm×10 cm. The cut pieces may then be packaged, usually into individual pouches, and sterilized in a conventional manner, for example using gamma irradiation, before being ready for use.
- to The results of making this change are illustrated by the following Examples
- The kier process described above and the process according to the invention were carried out separately on carboxymethylated lyocell having a degree of substitution of about 0.3. The kier process was carried out as described under ‘Background of the Invention’. The process according to the invention was carried out using a solution comprising 2.71 IMS, 1.81 water and 25 g AgNO3 on a hank of carboxymethylated lyocell dipped and immersed entirely in the solution over a period of about 5 seconds so that the hank took up the solution and thus all parts of the solution were in contact with the carboxymethylated lyocell and essentially all taken up. The silvered hank obtained in that way had an average silver content essentially the same as the hank treated by the kier process. In each case, the reacted tow was spread out lengthwise and allowed to dry, not in the dark but exposed to light. The material made using the kier showed extremely different extents of grey or pink with the majority of the tow uncoloured, typically 75%. The material made by the process of the invention was mostly grey/pink coloured with perhaps as little as about 5% to 10% uncoloured tow.
- The improvement was illustrated further when the tow was dried in the absence of daylight and cut/opened/carded/needled and examined as a piece of fabric. When these fabrics were exposed to intense daylight (eg 1000×standard) for 30 minutes the material made using the kier showed patchiness whereas the material made by the method of the invention was completely uniform in colour.
- As a further experiment not according to the invention, the tow of fibre, rather than being lowered as a hank, in about five seconds in all, was fed into the container of silvernitrate-containing solution as an end feed, hand over hand. This meant that it took about fifteen seconds to lower the tow into the solution. After the fibre had been dried, the tow was exposed to light to show the silver take-up visually and laid out side-by-side on a white bench top with the tow according to the invention as produced above.
- The tow lowered hand-over hand in an end feed was deeply coloured over about the first ⅓ to ½ of its length and the end to go in last was very lightly coloured and patchy. The hank-lowered tow was substantially uniformly coloured along its length.
- Two solutions of silver nitrate (1.58 g) in water (1 litre) were made up in the laboratory at room temperature. To the first was added alginate tow (100 g) in a deliberately slow manner, i.e. it took approximately 30 seconds to achieve full immersion. To the second was added a similar amount of alginate tow but this time in less than 5 seconds.
- Both tows were removed from the solution and, after squeezing out excess liquor, laid on the laboratory bench exposed to daylight. Soon afterwards but more so the following day, a vast difference was clearly visible. The slow-immersion tow was dark (due to discoloration caused by silver take-up) at one end of the tow but mostly uncoloured at the other end of the tow. The fast immersion tow was discoloured along the full length to a noticeably uniform extent.
- In a production situation the water-based solution would be replaced with an IMS/water-based solution to avoid filament adherence and gelling caused by hydrogen bonding when water only is used.
Claims (35)
1. An antibacterial wound dressing derived from gel-forming fibres having silver ions linked to not more than about 20% of the exchangeable sites on the gel-forming fibres, wherein the distribution of silver ions over the exchangeable sites is essentially uniform as shown by the uniform coloration of the dressing.
2. An antibacterial wound dressing according to claim 1 , wherein the silver ions are linked to not more than 10% of the exchangeable sites on the gel-forming fibres.
3. An antibacterial wound dressing according to claim 1 , wherein the gel forming fibres comprises lyocell-derived fibres.
4. An antibacterial wound dressing according to claim 1 , wherein the gel-forming fibres comprises carboxymethylated cellulose fibres.
5. An antibacterial wound dressing according to claim 1 , wherein the gel-forming fibres comprises calcium alginate or sodium/calcium alginate fibres
6. An antibacterial wound dressing according to claim 1 , wherein the silver content of the silvered fibres is from 0.01 to 10% by weight.
7. An antibacterial wound dressing according to claim 1 , wherein the silver content of the silvered fibres is from 0.1 to 5% by weight.
8. An antibacterial wound dressing according to claim 1 , wherein the silver content of the silvered fibres is from 0.5 to 2% by weight.
9. An antibacterial wound dressing according to claim 1 , wherein the silver content of the silvered fibres is from 0.9 to 1.5% by weight.
10. An antibacterial wound dressing according to claim 1 , wherein the antibacterial wound dressing is photostable.
11. An antibacterial wound dressing of claim 10 , wherein the wound dressing is treated with a metal halide.
12. An antibacterial wound dressing of claim 11 , wherein the metal halide is sodium chloride.
13. A process for producing silvered fibres for use in antibacterial wound dressings including the steps of
(i) forming an assembly of precursor gel-forming fibres having thereon exchangeable sites capable of exchange with silver ions to link silver ions to the fibre, and
(ii) essentially simultaneously contacting the assembly of precursor gel-forming fibres with a solution containing silver ions under conditions which do not cause irreversible gelling of the fibres, thereby to link silver ions at exchangeable sites, in which process the whole of the assembly of precursor gel-forming fibres is contacted essentially simultaneously with the entire solution containing silver ions, rather than being contacted gradually or partially, the solution containing silver ions being used in an amount such that enough silver ions are present to link with not more than about 20% of the exchangeable sites on the precursor gel-forming fibres, wherein the distribution of silver ions over the exchangeable sites is essentially uniform as shown by the essentially uniform coloration of the dressing.
14. A process according to claim 13 , wherein the silver ions are not linked with not more than about 10% of the exchangeable sites on the gel-forming fibres.
15. A process according to claim 13 , wherein the precursor gel-forming fibres comprises lyocell-derived fibres.
16. A process according to claim 13 , wherein the precursor gel-forming fibres comprises carboxymethylated cellulose fibres.
17. A process according to claim 13 , wherein the precursor gel-forming fibres comprises calcium alginate or sodium-calcium alginate fibres.
18. A process according to claim 13 , wherein the assembly of silvered, gel-forming fibres is further processed to form wound dressings.
18. A process according to claim 1 , wherein the wound dressings are photostable.
19. A process according to claim 18 , wherein the wound dressings are treated with a metal halide.
20. A process according to claim 18 , wherein the metal halide is sodium chloride.
21. A process according to claim 13 , wherein the silver content of the silvered fibres is from 0.01 to 10% by weight.
22. A process according to claim 13 , wherein the silver content of the silvered fibres is from 0.1 to 5% by weight.
23. A process according to claim 13 , wherein the silver content of the silvered fibres is from 0.5 to 2% by weight.
24. A process according to claim 13 , wherein the silver content of the silvered fibres is from 0.9 to 1.5% by weight.
25. A process according to claim 13 , wherein the silver content of the solution is between 0.1 to 1.0% w/v.
26. A process according to claim 13 , wherein the silver content of the solution is between 0.25 to 0.5% w/v.
27. A process according to claim 13 , wherein the silver content of the solution is 0.35% w/v.
28. A process according to claim 13 , in which the process is a batch process wherein the assembly of precursor gel-forming fibres is contacted with the solution containing silver ions by dipping it rapidly and entirely into the solution.
29. A process according to claim 28 , wherein the solution is held in a container and is an amount required completely to cover the precursor gel-forming fibres so that the fibres fill the solution within the container.
30. A process according to claim 28 , wherein the time interval between the beginning of the dipping of the assembly of precursor gel-forming fibres to form the wound dressing into the solution and the moment at which the assembly of precursor gel-forming fibres to form the wound dressing is entirely dipped into the solution is not more than about 10 seconds.
31. A process according to claim 30 , wherein said time interval is not more than 5 seconds.
32. A process according to claim 28 , wherein the assembly of precursor gel-forming fibres to be dipped is dry.
33. A process according to claim 29 , wherein the solution containing silver ions is held in a closed container.
34. A process according to claim 29 , wherein the solution containing silver ions is held in an open container.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/767,713 US20130152309A1 (en) | 2001-09-12 | 2013-02-14 | Antibacterial wound dressing |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0121946A GB0121946D0 (en) | 2001-09-12 | 2001-09-12 | Antibacterial material |
GB0121946.8 | 2001-09-12 | ||
GB0128329A GB0128329D0 (en) | 2001-11-27 | 2001-11-27 | Antibacterial material |
GB0128329.0 | 2001-11-27 | ||
PCT/GB2002/004131 WO2003022317A1 (en) | 2001-09-12 | 2002-09-11 | Antibacterial wound dressing |
US48830504A | 2004-03-01 | 2004-03-01 | |
US13/767,713 US20130152309A1 (en) | 2001-09-12 | 2013-02-14 | Antibacterial wound dressing |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/004131 Continuation WO2003022317A1 (en) | 2001-09-12 | 2002-09-11 | Antibacterial wound dressing |
US48830504A Continuation | 2001-09-12 | 2004-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130152309A1 true US20130152309A1 (en) | 2013-06-20 |
Family
ID=26246532
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/488,305 Active 2026-04-06 US8828424B2 (en) | 2001-09-12 | 2002-09-11 | Antibacterial wound dressing |
US13/767,713 Abandoned US20130152309A1 (en) | 2001-09-12 | 2013-02-14 | Antibacterial wound dressing |
US14/451,316 Expired - Fee Related US10342890B2 (en) | 2001-09-12 | 2014-08-04 | Antibacterial wound dressing |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/488,305 Active 2026-04-06 US8828424B2 (en) | 2001-09-12 | 2002-09-11 | Antibacterial wound dressing |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/451,316 Expired - Fee Related US10342890B2 (en) | 2001-09-12 | 2014-08-04 | Antibacterial wound dressing |
Country Status (16)
Country | Link |
---|---|
US (3) | US8828424B2 (en) |
EP (2) | EP1882482B2 (en) |
JP (1) | JP4800573B2 (en) |
KR (1) | KR100906901B1 (en) |
CN (1) | CN1553818B (en) |
AT (1) | ATE380041T1 (en) |
AU (1) | AU2002334063B2 (en) |
BR (1) | BR0212432A (en) |
CA (1) | CA2458708C (en) |
DE (1) | DE60223930T2 (en) |
DK (2) | DK1425050T3 (en) |
ES (2) | ES2295449T3 (en) |
MX (1) | MXPA04002231A (en) |
NZ (1) | NZ531635A (en) |
PT (2) | PT1882482E (en) |
WO (1) | WO2003022317A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9440001B2 (en) | 2013-03-06 | 2016-09-13 | Specialty Fibres and Materials Limited | Absorbent materials |
US10342890B2 (en) | 2001-09-12 | 2019-07-09 | Convatec Limited | Antibacterial wound dressing |
RU2700497C1 (en) * | 2019-04-26 | 2019-09-18 | Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" | Method for treating complicated biophosphonate osteomyelitis of jaw bones |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070009586A1 (en) * | 2000-02-29 | 2007-01-11 | Cohen Kelman I | Wound dressings containing complexes of transition metals and alginate for elastase sequestering |
EP1465673B1 (en) | 2001-12-20 | 2007-01-24 | Noble Fiber Technologies, LLC | Wound dressings comprising metallic silver |
US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
EP1610830A1 (en) * | 2003-03-28 | 2006-01-04 | Coloplast A/S | A wound dressing |
GB0325129D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
US7745509B2 (en) | 2003-12-05 | 2010-06-29 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US7909805B2 (en) | 2004-04-05 | 2011-03-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
US8062272B2 (en) | 2004-05-21 | 2011-11-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
US10058642B2 (en) | 2004-04-05 | 2018-08-28 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
WO2006105362A2 (en) * | 2005-03-29 | 2006-10-05 | Nucryst Pharmaceuticals Corp. | Biocompatible articles and related methods |
CN100339135C (en) * | 2005-05-13 | 2007-09-26 | 褚省吾 | Antibiotic aerogel dressing of hollow acetate fiber and its prepn |
CN102715984B (en) | 2005-09-06 | 2014-07-09 | 施乐辉股份有限公司 | Self contained wound dressing with micropump |
ES2534895T3 (en) | 2005-09-07 | 2015-04-30 | Smith & Nephew, Inc. | Self-wound wound dressing device |
MX2008002882A (en) | 2005-09-07 | 2008-03-27 | Tyco Healthcare | Wound dressing with vacuum reservoir. |
US20070083972A1 (en) * | 2005-09-26 | 2007-04-19 | Peter Francis | Rebel office shirt |
GB0525504D0 (en) | 2005-12-14 | 2006-01-25 | Bristol Myers Squibb Co | Antimicrobial composition |
US20070166399A1 (en) | 2006-01-13 | 2007-07-19 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
DE102006001954B4 (en) | 2006-01-16 | 2013-01-03 | Lohmann & Rauscher Gmbh & Co. Kg | Antiseptic alginate preparation, process for their preparation, and their use |
KR100788997B1 (en) | 2006-03-10 | 2007-12-28 | 김주영 | Method For Preparing Silver Bonded Antimicrobial Moist Wound Dressing And The Moist Wound Dressing |
DE102007030931A1 (en) * | 2007-07-03 | 2009-01-08 | Birgit Riesinger | Composition containing at least one nutritive, at least one disinfecting or decontaminating and / or at least one protease inhibiting active substance and / or active substance complex |
US7790946B2 (en) | 2007-07-06 | 2010-09-07 | Tyco Healthcare Group Lp | Subatmospheric pressure wound therapy dressing |
US8196874B2 (en) | 2007-10-12 | 2012-06-12 | Maxtec, Llc | Storable intravenous stands |
US8021347B2 (en) | 2008-07-21 | 2011-09-20 | Tyco Healthcare Group Lp | Thin film wound dressing |
US8298200B2 (en) | 2009-06-01 | 2012-10-30 | Tyco Healthcare Group Lp | System for providing continual drainage in negative pressure wound therapy |
US20090234306A1 (en) | 2008-03-13 | 2009-09-17 | Tyco Healthcare Group Lp | Vacuum wound therapy wound dressing with variable performance zones |
US9199012B2 (en) | 2008-03-13 | 2015-12-01 | Smith & Nephew, Inc. | Shear resistant wound dressing for use in vacuum wound therapy |
GB0805162D0 (en) * | 2008-03-19 | 2008-04-23 | Bristol Myers Squibb Co | Antibacterial wound dressing |
US10912869B2 (en) | 2008-05-21 | 2021-02-09 | Smith & Nephew, Inc. | Wound therapy system with related methods therefor |
US8177763B2 (en) | 2008-09-05 | 2012-05-15 | Tyco Healthcare Group Lp | Canister membrane for wound therapy system |
US8007481B2 (en) | 2008-07-17 | 2011-08-30 | Tyco Healthcare Group Lp | Subatmospheric pressure mechanism for wound therapy system |
US8048046B2 (en) | 2008-05-21 | 2011-11-01 | Tyco Healthcare Group Lp | Wound therapy system with housing and canister support |
US8257326B2 (en) | 2008-06-30 | 2012-09-04 | Tyco Healthcare Group Lp | Apparatus for enhancing wound healing |
JP5571663B2 (en) | 2008-07-08 | 2014-08-13 | スミス アンド ネフュー インコーポレイテッド | Portable negative pressure wound therapy device |
JP5502083B2 (en) | 2008-08-08 | 2014-05-28 | スミス アンド ネフュー インコーポレイテッド | Continuous fiber wound dressing |
US8216198B2 (en) * | 2009-01-09 | 2012-07-10 | Tyco Healthcare Group Lp | Canister for receiving wound exudate in a negative pressure therapy system |
US8827983B2 (en) | 2008-08-21 | 2014-09-09 | Smith & Nephew, Inc. | Sensor with electrical contact protection for use in fluid collection canister and negative pressure wound therapy systems including same |
US8251979B2 (en) | 2009-05-11 | 2012-08-28 | Tyco Healthcare Group Lp | Orientation independent canister for a negative pressure wound therapy device |
US9414968B2 (en) | 2008-09-05 | 2016-08-16 | Smith & Nephew, Inc. | Three-dimensional porous film contact layer with improved wound healing |
GB2463523B (en) | 2008-09-17 | 2013-05-01 | Medtrade Products Ltd | Wound care device |
US8162907B2 (en) | 2009-01-20 | 2012-04-24 | Tyco Healthcare Group Lp | Method and apparatus for bridging from a dressing in negative pressure wound therapy |
US8246591B2 (en) | 2009-01-23 | 2012-08-21 | Tyco Healthcare Group Lp | Flanged connector for wound therapy |
US8167869B2 (en) | 2009-02-10 | 2012-05-01 | Tyco Healthcare Group Lp | Wound therapy system with proportional valve mechanism |
US20110196321A1 (en) | 2009-06-10 | 2011-08-11 | Tyco Healthcare Group Lp | Fluid Collection Canister Including Canister Top with Filter Membrane and Negative Pressure Wound Therapy Systems Including Same |
US20100324516A1 (en) | 2009-06-18 | 2010-12-23 | Tyco Healthcare Group Lp | Apparatus for Vacuum Bridging and/or Exudate Collection |
EP2496239B1 (en) * | 2009-11-06 | 2018-01-03 | Care Fusion 2200, Inc. | Copper salts of ion exchange materials for use in the treatment and prevention of infections |
CN102371003A (en) * | 2010-08-18 | 2012-03-14 | 张德华 | Water-soluble fiber fabric wound dressing and preparation method thereof |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
US9302034B2 (en) | 2011-04-04 | 2016-04-05 | Smith & Nephew, Inc. | Negative pressure wound therapy dressing |
WO2012168678A1 (en) | 2011-06-07 | 2012-12-13 | Smith & Nephew Plc | Wound contacting members and methods |
KR101361629B1 (en) * | 2012-12-10 | 2014-02-13 | 한국생산기술연구원 | Manufacturing method of wet-laid carboxymethyl cellulose nonwoven and use of using the same |
CN105008611A (en) | 2012-12-20 | 2015-10-28 | 康沃特克科技公司 | Processing of chemically modified cellulosic fibres |
CA2956572C (en) | 2014-07-31 | 2023-06-27 | Smith & Nephew, Inc. | Systems and methods for applying reduced pressure therapy |
CN107708754B (en) * | 2015-04-28 | 2021-08-06 | 康沃特克科技公司 | Antibacterial nanofiber |
CN104958779B (en) * | 2015-06-25 | 2018-03-20 | 佛山市优特医疗科技有限公司 | A kind of wound dressing containing chelating silver fiber |
EP3632477B1 (en) | 2017-05-23 | 2024-03-20 | Huizhou Foryou Medical Devices Co., Ltd. | Antibacterial wound dressing and preparation method and application thereof |
US11406525B2 (en) | 2017-11-09 | 2022-08-09 | 11 Health And Technologies Limited | Ostomy monitoring system and method |
USD893514S1 (en) | 2018-11-08 | 2020-08-18 | 11 Health And Technologies Limited | Display screen or portion thereof with graphical user interface |
GB2588442A (en) | 2019-10-24 | 2021-04-28 | Io Cyte Ltd | Antimicrobial material |
GB2588440A (en) | 2019-10-24 | 2021-04-28 | Io Cyte Ltd | Swellable antimicrobial fibre |
DE102020133583A1 (en) * | 2020-12-15 | 2022-06-15 | Lohmann & Rauscher Gmbh | Method of making a wound care product and wound care product |
US11780312B1 (en) * | 2022-12-23 | 2023-10-10 | Jay Stephen Kaufman | Exhaust gas heat recovery from cryo-compression engines with cogeneration of cryo-working fluid |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5709870A (en) * | 1994-10-18 | 1998-01-20 | Rengo Co., Ltd. | Antimicrobial agent |
US6835678B2 (en) * | 2000-05-04 | 2004-12-28 | Kimberly-Clark Worldwide, Inc. | Ion sensitive, water-dispersible fabrics, a method of making same and items using same |
US6897349B2 (en) * | 1997-11-14 | 2005-05-24 | Acrymed | Silver-containing compositions, devices and methods for making |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887088A (en) † | 1954-08-16 | 1959-05-19 | Ohio Commw Eng Co | Apparatus for gaseous metal plating fibers |
NL255008A (en) | 1959-08-18 | |||
GB1328088A (en) | 1969-09-27 | 1973-08-30 | Wallace Cameron Co Ltd | Solubilized alginic materials |
DE2639287C2 (en) | 1976-09-01 | 1978-09-28 | Basf Ag, 6700 Ludwigshafen | Process for the deposition of silver layers on non-metallic, in particular ceramic, carrier material |
US4393048A (en) † | 1980-02-15 | 1983-07-12 | The United States Of America As Represented By The Secretary Of The Army | Protective gel composition for wounds |
JPS61243182A (en) | 1985-04-19 | 1986-10-29 | Nitsukan Kogyo Kk | Potassium titanate fibers plated with metal and its production |
US4643918A (en) * | 1985-05-03 | 1987-02-17 | Material Concepts, Inc. | Continuous process for the metal coating of fiberglass |
US4728323A (en) † | 1986-07-24 | 1988-03-01 | Minnesota Mining And Manufacturing Company | Antimicrobial wound dressings |
JP2894493B2 (en) | 1988-02-09 | 1999-05-24 | 三菱マテリアル株式会社 | Method for producing silver-coated organic fiber |
PT91689B (en) * | 1988-09-12 | 1995-05-31 | Johnson & Johnson Patient Care | PROCESS FOR THE PREPARATION OF AN ADHESIVE BACTERICIDE COMPOSITION |
JPH02153076A (en) | 1988-12-02 | 1990-06-12 | Agency Of Ind Science & Technol | Production of copper-silver two-layer coated powder |
GB9001878D0 (en) | 1990-01-26 | 1990-03-28 | Beam Tech Ltd | Alginate materials |
US5186984A (en) | 1990-06-28 | 1993-02-16 | Monsanto Company | Silver coatings |
JP2777279B2 (en) * | 1990-10-08 | 1998-07-16 | 工業技術院長 | Wound dressing and method for producing the same |
FR2671113B1 (en) * | 1990-12-27 | 1994-05-20 | Michelin Et Cie | PLASMA TREATMENT OF AN ARAMID MONOFILAMENT AND MONOFILAMENT THUS OBTAINED. |
EP0577724B1 (en) | 1991-03-25 | 1996-07-31 | E.I. Du Pont De Nemours And Company | Electroless plated aramid surfaces |
WO1992022285A1 (en) * | 1991-06-14 | 1992-12-23 | Viaderm Pharmaceuticals, Inc. | Alginate wound dressings |
US5180585A (en) † | 1991-08-09 | 1993-01-19 | E. I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
GB9126193D0 (en) | 1991-12-10 | 1992-02-12 | Courtaulds Plc | Cellulosic fibres |
US5681575A (en) † | 1992-05-19 | 1997-10-28 | Westaim Technologies Inc. | Anti-microbial coating for medical devices |
US5302415A (en) | 1992-12-08 | 1994-04-12 | E. I. Du Pont De Nemours And Company | Electroless plated aramid surfaces and a process for making such surfaces |
JPH06200472A (en) * | 1992-12-28 | 1994-07-19 | Suntory Ltd | Antimicrobial fiber, its production and material made of fiber |
GB9301258D0 (en) | 1993-01-22 | 1993-03-17 | Courtaulds Plc | Use of absorbent fibre |
WO1994016746A1 (en) | 1993-01-22 | 1994-08-04 | Courtaulds Plc | Wound dressings |
JPH06235116A (en) * | 1993-02-08 | 1994-08-23 | Asahi Chem Ind Co Ltd | Antimicrobial fiber and web |
JPH06264365A (en) * | 1993-03-11 | 1994-09-20 | Sekisui Plastics Co Ltd | Antimicrobial fiber |
GB9400994D0 (en) * | 1994-01-20 | 1994-03-16 | Bristol Myers Squibb Co | Wound dressing |
JP3401076B2 (en) * | 1994-02-28 | 2003-04-28 | 株式会社メイセイ | Manufacturing method of antibacterial fiber |
GB9414305D0 (en) * | 1994-07-15 | 1994-09-07 | C V Lab Ltd | Alginate fibre, process for the preparation thereof and use |
JPH08176961A (en) * | 1994-12-26 | 1996-07-09 | New Oji Paper Co Ltd | Antimicrobial complex nonwoven fabric sheet |
US6087549A (en) † | 1997-09-22 | 2000-07-11 | Argentum International | Multilayer laminate wound dressing |
JP3693449B2 (en) * | 1996-04-05 | 2005-09-07 | 三菱製紙株式会社 | Antibacterial antifungal agent and fibrous substance containing the same |
ATE202388T1 (en) * | 1996-04-12 | 2001-07-15 | Bristol Myers Squibb Co | COMPOSITE FIBERS, WOUND DRESSINGS CONTAINING SUCH FIBERS AND METHOD FOR THE PRODUCTION THEREOF |
GB9618573D0 (en) † | 1996-09-05 | 1996-10-16 | Courtaulds Fibres Holdings Ltd | Wound dressings and manufacture thereof |
CN1067281C (en) * | 1997-05-22 | 2001-06-20 | 吴湘君 | Cohesive and hydrophilic gel for medical use, and method for preparing same |
JPH11103696A (en) * | 1997-10-02 | 1999-04-20 | Mitsubishi Paper Mills Ltd | Agricultural sheet having antibacterial and antifungal activity |
JPH11107501A (en) * | 1997-10-03 | 1999-04-20 | Mitsubishi Paper Mills Ltd | Tatami mat and underlay sheet having antibacterial and mildewproof function |
CN1204928C (en) * | 1998-07-01 | 2005-06-08 | 厄苛迪斯特制纤维有限公司 | Wound dressings and their prep., and material suitable for use therein |
JP4415421B2 (en) * | 1999-04-28 | 2010-02-17 | 日本エクスラン工業株式会社 | Antibacterial acrylonitrile fiber and process for producing the same |
JP2001057931A (en) * | 1999-08-23 | 2001-03-06 | Mitsubishi Paper Mills Ltd | Deodorizing antibacterial sheet |
WO2001024839A1 (en) * | 1999-10-01 | 2001-04-12 | Acrymed | Silver-containing compositions, devices and methods for making |
GB2370226A (en) * | 2000-09-21 | 2002-06-26 | Acordis Speciality Fibres Ltd | Wound dressing |
GB0026863D0 (en) | 2000-11-03 | 2000-12-20 | Ssl Int Plc | Polysaccharide fibres |
ES2343675T3 (en) | 2000-11-29 | 2010-08-06 | Convatec Technologies Inc. | ANTIMICROBIAL MATERIALS STABILIZED AGAINST LIGHT. |
AU2002334063B2 (en) | 2001-09-12 | 2008-08-14 | Acordis Speciality Fibres Limited | Antibacterial wound dressing |
-
2002
- 2002-09-11 AU AU2002334063A patent/AU2002334063B2/en not_active Expired
- 2002-09-11 ES ES02798011T patent/ES2295449T3/en not_active Expired - Lifetime
- 2002-09-11 EP EP07021890.4A patent/EP1882482B2/en not_active Expired - Lifetime
- 2002-09-11 ES ES07021890T patent/ES2390480T3/en not_active Expired - Lifetime
- 2002-09-11 PT PT07021890T patent/PT1882482E/en unknown
- 2002-09-11 CN CN028175913A patent/CN1553818B/en not_active Expired - Lifetime
- 2002-09-11 US US10/488,305 patent/US8828424B2/en active Active
- 2002-09-11 AT AT02798011T patent/ATE380041T1/en active
- 2002-09-11 JP JP2003526445A patent/JP4800573B2/en not_active Expired - Fee Related
- 2002-09-11 WO PCT/GB2002/004131 patent/WO2003022317A1/en active Search and Examination
- 2002-09-11 NZ NZ531635A patent/NZ531635A/en not_active IP Right Cessation
- 2002-09-11 BR BR0212432-7A patent/BR0212432A/en not_active Application Discontinuation
- 2002-09-11 PT PT02798011T patent/PT1425050E/en unknown
- 2002-09-11 EP EP02798011A patent/EP1425050B1/en not_active Expired - Lifetime
- 2002-09-11 DK DK02798011T patent/DK1425050T3/en active
- 2002-09-11 MX MXPA04002231A patent/MXPA04002231A/en active IP Right Grant
- 2002-09-11 DE DE60223930T patent/DE60223930T2/en not_active Expired - Lifetime
- 2002-09-11 CA CA2458708A patent/CA2458708C/en not_active Expired - Lifetime
- 2002-09-11 KR KR1020047002601A patent/KR100906901B1/en active IP Right Grant
- 2002-09-11 DK DK07021890.4T patent/DK1882482T3/en active
-
2013
- 2013-02-14 US US13/767,713 patent/US20130152309A1/en not_active Abandoned
-
2014
- 2014-08-04 US US14/451,316 patent/US10342890B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5709870A (en) * | 1994-10-18 | 1998-01-20 | Rengo Co., Ltd. | Antimicrobial agent |
US6897349B2 (en) * | 1997-11-14 | 2005-05-24 | Acrymed | Silver-containing compositions, devices and methods for making |
US6835678B2 (en) * | 2000-05-04 | 2004-12-28 | Kimberly-Clark Worldwide, Inc. | Ion sensitive, water-dispersible fabrics, a method of making same and items using same |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10342890B2 (en) | 2001-09-12 | 2019-07-09 | Convatec Limited | Antibacterial wound dressing |
US9440001B2 (en) | 2013-03-06 | 2016-09-13 | Specialty Fibres and Materials Limited | Absorbent materials |
RU2700497C1 (en) * | 2019-04-26 | 2019-09-18 | Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" | Method for treating complicated biophosphonate osteomyelitis of jaw bones |
Also Published As
Publication number | Publication date |
---|---|
EP1882482B1 (en) | 2012-07-11 |
BR0212432A (en) | 2004-08-17 |
US10342890B2 (en) | 2019-07-09 |
EP1882482A3 (en) | 2008-08-27 |
CA2458708C (en) | 2011-08-02 |
KR20040044470A (en) | 2004-05-28 |
EP1882482B2 (en) | 2022-03-30 |
EP1425050B1 (en) | 2007-12-05 |
EP1425050A1 (en) | 2004-06-09 |
ES2295449T3 (en) | 2008-04-16 |
CN1553818A (en) | 2004-12-08 |
JP4800573B2 (en) | 2011-10-26 |
DE60223930D1 (en) | 2008-01-17 |
CN1553818B (en) | 2011-03-16 |
AU2002334063B2 (en) | 2008-08-14 |
JP2005501982A (en) | 2005-01-20 |
US20040241213A1 (en) | 2004-12-02 |
DK1882482T3 (en) | 2012-10-08 |
WO2003022317A1 (en) | 2003-03-20 |
US20140356454A1 (en) | 2014-12-04 |
ES2390480T3 (en) | 2012-11-13 |
KR100906901B1 (en) | 2009-07-08 |
ATE380041T1 (en) | 2007-12-15 |
DE60223930T2 (en) | 2008-11-06 |
DK1425050T3 (en) | 2008-01-07 |
PT1882482E (en) | 2012-08-01 |
NZ531635A (en) | 2005-04-29 |
MXPA04002231A (en) | 2005-03-07 |
US8828424B2 (en) | 2014-09-09 |
CA2458708A1 (en) | 2003-03-20 |
EP1882482A2 (en) | 2008-01-30 |
PT1425050E (en) | 2008-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10342890B2 (en) | Antibacterial wound dressing | |
AU2002334063A1 (en) | Antibacterial wound dressing | |
US10391197B2 (en) | Silver containing wound dressing | |
US5482932A (en) | Alginate gels to the form of fibrous pastes useful as wound dressings | |
DE60111240T2 (en) | PREPARATION OF ARTICLES WITH CONTACT BIOCIDAL PROPERTIES | |
CN104958779B (en) | A kind of wound dressing containing chelating silver fiber | |
WO2021079126A1 (en) | Antimicrobial material | |
JPH08197508A (en) | Manufacture of bark chip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |